A5037296210- Dialysis and Renal Disease Management
- COVID-19 Clinical Research Studies
- COVID-19 and Mental Health
- Central Venous Catheters and Hemodialysis
- Potassium and Related Disorders
- Renal function and acid-base balance
- Lipoproteins and Cardiovascular Health
- SARS-CoV-2 and COVID-19 Research
- Renal and Vascular Pathologies
- Acute Myeloid Leukemia Research
- Vascular anomalies and interventions
- Cancer, Lipids, and Metabolism
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Multiple Myeloma Research and Treatments
- Hormonal and reproductive studies
- Chronic Myeloid Leukemia Treatments
- Blood Pressure and Hypertension Studies
- Organ Donation and Transplantation
- Pharmacology and Obesity Treatment
- Long-Term Effects of COVID-19
- Chronic Kidney Disease and Diabetes
- Peripheral Artery Disease Management
- Chronic Lymphocytic Leukemia Research
- Hemophilia Treatment and Research
- Thyroid and Parathyroid Surgery
Fundación Arturo López Pérez
2020-2024
Hospital Universitario Ramón y Cajal
1993-2016
Instituto Ramón y Cajal de Investigación Sanitaria
2016
Universidad de Alcalá
2003
Convalescent plasma (CP), despite limited evidence on its efficacy, is being widely used as a compassionate therapy for hospitalized patients with COVID-19. We aimed to evaluate the efficacy and safety of early CP in COVID-19 progression.The study was an open-label, single-center randomized clinical trial performed academic medical center Santiago, Chile, from May 10, 2020, July 18, final follow-up until August 17, 2020. The included within first 7 days symptom onset, presenting risk factors...
Abstract Background Convalescent plasma (CP), despite limited evidence on its efficacy, is being widely used as a compassionate therapy for hospitalized patients with COVID-19. We aimed to evaluate the efficacy and safety of early CP in COVID-19 progression. Methods Open-label, single-center, randomized clinical trial performed an academic center Santiago, Chile from May 10, 2020, July 18, final follow-up August 17, 2020. The included within first 7 days symptoms onset, presenting risk...
Plasma cell leukemia (PCL) is a clinically aggressive variant of multiple myeloma, characterized by high burden circulating plasma cells, necessitating swift and accurate diagnosis due to its poor prognosis. The conventional diagnostic criteria, including the recent recommendation International Myeloma Working Group (IMWG) > 5% cells as positive, have evolved over time. In this context, we present detailed case report that underscores pivotal role ADVIA 2120 automated hematology counter...
COVID-19 is a pandemic caused by SARS-CoV-2. In Chile, half million people have been infected and more than 16,000 died from COVID-19. As part of the clinical trial NCT04384588, we quantified IgG against S1-RBD SARS-CoV-2 (anti-RBD) in recovered Santiago evaluated their suitability as convalescent plasma donors. ELISA luminescent pseudotype were used for neutralizing antibody quantification. 72.9% population (468 639) showed seroconversion (5-55 μg/mL anti-RBD IgG) suitable candidates...
Presentamos una nueva edición de la Guía Centros Hemodiálisis. Se enmarca en el programa actualización las Guías Clínicas Sociedad Española Nefrología. Es un documento consenso que han colaborado nefrólogos con amplia experiencia diálisis y expertos enfermería nefrológica. La ha sido corregida por grupo evaluadores externos. informado se tomado consideración opinión los pacientes a través Asociación Enfermos Renales (ALCER). Esta incluye sus diez capítulos aspectos arquitectónicos,...
Abstract Background The use of convalescent plasma (CP) to treat COVID-19 has shown promising results; however, its effectiveness remains uncertain. purpose this study was determine the safety and mortality CP among patients hospitalized with COVID-19. Study Design Methods This multicenter, open-label, uncontrolled clinical trial is currently being conducted at nine hospitals in Chile. Patients due who were still within 14 days since symptom onset classified into four groups: cancer severe...